Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Theriva Biologics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +1 vs. Q3 2025
- Shares held
- 1.30M
- +858.5K (+196.4%) vs. Q3 2025
- Total value
- $272.4K
- +$95.3K (+53.9%) vs. Q3 2025
- New holders
- 7
- 7 more added
- Sold out
- 6
- 4 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TOVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $495.5K |
| Q1 2026 | 22 | $385.4K |
| Q4 2025 | 21 | $272.4K |
| Q3 2025 | 20 | $177.0K |
| Q2 2025 | 17 | $126.3K |
| Q1 2025 | 11 | $209.8K |
| Q4 2024 | 10 | $60.3K |
| Q3 2024 | 18 | $678.6K |
| Q2 2024 | 22 | $327.6K |
| Q1 2024 | 24 | $366.3K |
| Q4 2023 | 24 | $452.3K |
| Q3 2023 | 21 | $572.8K |
| Q2 2023 | 18 | $1.01M |
| Q1 2023 | 19 | $724.6K |
| Q4 2022 | 22 | $477.1K |
| Q3 2022 | 26 | $1.15M |
| Q2 2022 | 33 | $2.51M |
| Q1 2022 | 35 | $3.17M |
| Q4 2021 | 35 | $3.24M |
| Q3 2021 | 36 | $3.32M |
| Q2 2021 | 31 | $3.91M |
| Q1 2021 | 32 | $5.80M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Theriva Biologics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 255,727 | $53.7K | 0.00% | +239,345+1,461.0% | Added |
| Geode Capital Management, LLC | 212,087 | $44.6K | 0.00% | +183,878+651.8% | Added |
| Morgan Stanley | 200,000 | $42.1K | 0.00% | +200,000 | New |
| UBS Group AG | 191,410 | $40.2K | 0.00% | +168,497+735.4% | Added |
| Ikarian Capital, LLC | 112,076 | $23.6K | 0.00% | −7,955−6.6% | Reduced |
| Two Sigma Securities, LLC | 42,893 | $9.03K | 0.00% | +42,893 | New |
| Two Sigma Investments, LP | 42,337 | $8.91K | 0.00% | −19,500−31.5% | Reduced |
| DRW Securities, LLC | 41,745 | $8.78K | 0.00% | +41,745 | New |
| XTX Topco Ltd | 39,445 | $8.30K | 0.00% | +6,546+19.9% | Added |
| StoneX Group Inc. | 37,217 | $7.83K | 0.00% | +37,217 | New |
| Barclays PLC | 32,569 | $6.85K | 0.00% | +32,569 | New |
| Bank of America Corp | 31,139 | $6.54K | 0.00% | +31,058+38,343.2% | Added |
| Boothbay Fund Management, LLC | 27,646 | $5.82K | 0.00% | −7,955−22.3% | Reduced |
| Schwarz Dygos Wheeler Investment Advisors LLC | 15,000 | $3.16K | 0.00% | +15,000 | New |
| BlackRock, Inc. | 7,504 | $1.58K | 0.00% | −20.0% | Reduced |
| Citigroup Inc | 6,189 | $1.30K | 0.00% | +6,188+618,800.0% | Added |
| Advisor Group Holdings, Inc. | 448 | $93 | 0.00% | +4+0.9% | Added |
| SBI Securities Co., Ltd. | 59 | $12 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 11 | $2 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 5 | $1 | 0.00% | +5 | New |
| Danske Bank A/S | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 0 | $0 | 0.00% | −36,781−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −36,771−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −27,284−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −10,142−100.0% | Sold out |
| Clear Street Group Inc. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Wealthspire Advisors, LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |